Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Ali Sadoughi

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0896c190-56c0-11ec-a12b-63debfbf42ce.jpg

First Name

Ali

Last Name

Sadoughi

NPI

1699933879

Faculty ID

14807

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Ali Sadoughi is Director of Interventional Pulmonology and Bronchoscopy. His clinical expertise is in interventional pulmonology and thoracic oncology, an evolving sub-specialty of pulmonary and critical care medicine. This field focuses on patients with benign and malignant chest diseases.</p>
<p>Dr. Sadoughi performs advanced diagnostic and therapeutic procedures for patients with lung nodules/masses, intra-thoracic lymphadenopathy, pleural diseases, and severe asthma. These include:</p>
<ul>
<li>Sampling of pulmonary lesions; both peripherally and centrally located in the lung; using endobronchial ultrasound (EBUS, both radial and linear array probes) and navigational bronchoscopy</li>
<li>Therapeutic rigid and flexible bronchoscopy on patients with major airway disorders, including tumor de-bulking, airway dilatation and stent placement</li>
<li>Diagnostic and therapeutic procedures on patients with pleural disease and effusion</li>
<li>Therapeutic interventions such as pleurodesis, tunneled pleural catheter and chest tube placement</li>
<li>Bronchial thermoplasty for severe asthma&nbsp;</li>
<li>Endobronchial valve placement for persistent air leak from the lung</li>
</ul>
<p>His other&nbsp;experience is in ultrasonography and echocardiography and their applications in pulmonary and critical care medicine.</p>
<p>Dr. Sadoughi's research interests are in evolution and application of sophisticated and modern technologies for early and minimally invasive diagnosis and treatment of different pulmonary diseases, from lung cancers, to airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure, and pleural diseases. The outcome of his research studies in pulmonary hypertension and interventional pulmonology has been published in high-ranking medical journals and presented in different national conferences.</p>
<h3>Clinical Specialties</h3>
<ul>
<li>Pulmonary Medicine
<ul>
<li>Interventional Pulmonology</li>
<li>Lung Cancer</li>
</ul>
</li>
<li>Critical Care</li>
</ul>
<h3>Board Certification</h3>
<ul>
<li>Pulmonary Disease</li>
<li>Critical Care Medicine</li>
<li>Internal Medicine</li>
</ul>
<h3>Education &amp; Training</h3>
<ul>
<li>Medical School: Shahid Beheshti University of Medical Sciences</li>
<li>Residency: Kingsbrook Jewish Medical Center</li>
<li>Fellowship: Hofstra-North Shore LIJ School of Medicine</li>
<li>Fellowship: Washington University in Saint Louis</li>
</ul>
<h3>Professional Memberships</h3>
<ul>
<li>American Association of Bronchology and Interventional Pulmonology (AABIP), Member</li>
<li>American College of Chest Physicians (ACCP), Member</li>
<li>American Thoracic Society (ATS), Member</li>
<li>International Association for the Study of Lung Cancer&nbsp;(IASLC),&nbsp;Member</li>
</ul>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sadoughi specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.

Elsevier Profile

Selected Publications

<ol>
<li>Bronchomediastinal Fistula From Erosion of Surgical Pledgets Into the Airway, Sadoughi A, Meyers B, Chenna P, Chest. 2015;148:838A. doi:10.1378/chest.2261266</li>
<li>Obstruction of the Trachea with Necrotic Tissue from a Pleomorphic Lung Carcinoma,&nbsp;Sadoughi A, Hyman K, Patel D, Chest. 2014;146:768A. doi:10.1378/chest.1991851.</li>
<li>Diagnosis and Safe Ablation of Endobronchial Hamartoma with Interventional Bronchoscopy,&nbsp;Sadoughi A, Folch E, Majid A. Am J Respir Crit Care Med 189;2014:A4447.</li>
<li>Macrophage migration inhibitory factor mediates hypoxia- induced pulmonary hypertension, Yinzhong Zhang, Arunabh Talwar, Donna Tsang, Annette Bruchfeld, Ali Sadoughi, Maowen Hu, Kennedy Omonuwa, Kai Fan Cheng, Yousef Al-Abed, and Edmund J. Miller, Molecular Medicine, Nov 2011, PMID: 22113497.</li>
<li>Impaired Heart Rate Recovery After Cardio Pulmonary Exercise Testing [CPET] In Patients with Pulmonary Arterial Hypertension, Arunabh Talwar MD, Ali Sadoughi&nbsp; MD,&nbsp; Purvesh&nbsp; Patel MD,&nbsp; Tara George, Donna Tsang, Nina Kohn MS; Chest. 2011;140(4_MeetingAbstracts):723A. doi:10.1378/chest.1119783</li>
<li>A 77-year-old woman with dyspnea and Reynaud phenomenon. Wang J, Sadoughi A, Dedopoulos S, Talwar A, Chest. 2011 Apr;139(4):958-6. PMID: 21467065</li>
<li>Intracranial Pressure Treatment Tailored to Transcranial Doppler-Derived Compliance and Perfusion. Kapinos G, Sadoughi A, Narayan R, oral presentation, November 2013 at the 15th International Conference on Intracranial Pressure and Brain Monitoring, Singapore.</li>
<li>Management of Increased Intracranial Pressure. Sadoughi A, Rybinnik I, Cohen R. The Open Critical Care Medicine Journal, 2013, 6, (Suppl 1: M4) 56-65.</li>
<li>Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension, Sadoughi A, Roberts K, Preston I, Lai GP, Mcollister D, Farber HW, Hill NS, Chest. 2013 Apr 4. PMID: 23558791.</li>
<li>Inflammatory Mechanisms in Pulmonary Hypertension, A Sadoughi, Y Zhang, EJ Miller, A Talwar; <em>CML (Current Medical Literature) &ndash; Pulmonary Hypertension </em>2010;1(4):93&ndash;106.</li>
<li>Computed Tomography Angiogram of the Chest as a Valuable Predicting Tool for Pulmonary Arterial Hypertension, A Sadoughi, N Patel, J Wang, N Kohn, R Shah, A Talwar; Chest. 2010;138(4_MeetingAbstracts):357A. doi:10.1378/chest.10559</li>
<li>Arterial Concentration of Macrophage Migration Inhibitory Factor (MIF) increases with exercise in patients with pulmonary Hypertension (PH), A Sadoughi, EJ Miller, A Talwar, presented at FOCIS 2011, Washington, DC.</li>
<li>Utility of Pulmonary Artery Diameter in Computed Tomography of Chest as a screening tool for Pulmonary Arterial Hypertension, A Sadoughi, T Chandak, N Kohn, R Shah, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>Relationship of Pulmonary Arterial Oxygen Saturation with Right Atrial Pressure in Pulmonary Hypertension, T Chandak, A Sadoughi, N Kohn, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>A case of Portopulmonary Hypertension, Sadoughi A, Mukherji R, Mehra S, Talwar A, The Journal of Respiratory Diseases, September, 2008.</li>
<li>Arteriotomy Closure Device Application Following Percutaneous Coronary Intervention May Prevent Bleeding Complication in Patients with Acute Myocardial Infarction, F. Ikeno, M. Ali Sadoughi, J. Lyons, F. Raissi, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kaneda, A. C. Yeung, M. Rezaee, International J. of Cardiology, April 2007, 117(1), 131-132, PMID:16935367.</li>
<li>The Conversion in Application of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, F. Ikeno, F. Raissi, M. Ali Sadoughi, J.K. Lyons, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kanada, A.C. Yeung, M. Rezaee, International Journal of Cardiology, November 2006, 113(2), 279-280, PMID: 16318883.</li>
<li>Drug-eluting stents alter referral patterns for revascularization in patients with multivessel coronary artery disease, HMO Farouque, Fearon WF, Wu BM, Luna J, Shabari FR, Sadoughi MA, Lee DP, Yeung AC, Heart, Lung, Circulation 2005; 14 Suppl 1: S77, Australia</li>
<li>Changes in the Practice of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, Raissi F., Sadoughi M.A., Hashemi V., Pourdehmobed K., Farouque O., Lyons J., Emami S., Ikeno F., Kaneda H., Yeung A.C., Rezaee M., TCT (Transcatheter Cardiovascular Therapeutics) meeting 2004, Washington DC, Poster Presentation, 09 / 2004.</li>
</ol>

EMR ID

78160

Biography

<p>Ali Sadoughi, MD, is Director, Interventional Pulmonology and Bronchoscopy and Associate Professor, Medicine at Montefiore Einstein. He specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.</p><p>After earning his Doctor of Medicine at Shahid Beheshti University of Medical Sciences in Tehran, Iran, Dr. Sadoughi completed an internal medicine residency at Kingsbrook Jewish Medical Center. Following this, he completed a pulmonary and critical care fellowship at Hofstra-North Shore LIJ School of Medicine in 2014 and an interventional pulmonary fellowship at Washington University in 2015.</p><p>Dr. Sadoughi's research interests are in developing and applying advanced technologies for early and minimally invasive diagnosis and treatment of pulmonary diseases. These include lung cancers, airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure and pleural diseases. His work has been published in journals including <em>Chest</em> and the <em>Journal of Molecular Medicine</em>, and he has made presentations at national and international medical meetings. One of his recent research studies focuses on the development of brachytherapy seeds (DaRT) using alpha radiation for the treatment of lung cancer, sponsored by Alpha Tau Ltd. In another study, he works with an international group of pulmonologists on the role of confocal laser endomicroscopy (CLE) in the diagnosis of different benign and malignant lung diseases. His work related to increased precision and accuracy of biopsy of peripheral lung nodules by intraprocedural 3D scanning in combination with ultrathin bronchoscopy has been published in the <em>Journal of Bronchology and Interventional Pulmonology</em>. Another area of Dr. Sadoughi&rsquo;s research involves the synergy of local therapies such as cryotherapy with immunotherapy in the treatment of lung cancer. He has presented this exciting topic at the American Association of Bronchology and Interventional Pulmonology (AABIP) Conference in 2022.</p><p>Dr. Sadoughi is board certified in interventional pulmonology, pulmonary disease, critical care medicine and internal medicine. He is a member of professional societies such as the American Association of Bronchology and Interventional Pulmonology, the World Association of Bronchology and Interventional Pulmonology, the American College of Chest Physicians, the American Thoracic Society and the International Association for the Study of Lung Cancer. He has contributed his research to the U.S. News, Politico New York and OncLive, and has been an editorial member and reviewer of multiple medical journals.</p>

Is Open Scheduling

On

Norman L. Rosen

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Norman

Last Name

Rosen

NPI

1053492215

Faculty ID

4387

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3442

Is Open Scheduling

Off

Mark A. Ramirez

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ramirez_Mark_MD.jpg

First Name

Mark

Last Name

Ramirez

NPI

1467494336

Faculty ID

3064

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3582

Is Open Scheduling

Off

Joshua P. Raff

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f591cd20-c723-11ee-a272-67239916ef55.jpg

First Name

Joshua

Last Name

Raff

NPI

1689672362

Faculty ID

18177

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

4127

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Sun Young Oh

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/25418200-f8b2-11ec-9cb7-15f799598473.jpg

First Name

Sun Young

Last Name

Oh

NPI

1174887699

Faculty ID

14930

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">The clinical focus is on medical oncology and the systemic treatment of breast cancer.</span>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Oh&rsquo;s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</span>

Elsevier Profile

EMR ID

55194

Biography

<p>Sun Young Oh, MD, is an Oncologist and Assistant Professor, Oncology and Medicine at Montefiore Einstein. Her clinical focus is on medical oncology and the systemic treatment of breast cancer.</p><p>In 2003, Dr. Oh completed her Doctor of Medicine at Ewha Womans University in Seoul, South Korea. She pursued postdoctoral training in the United States completing her internal medicine internship at Lutheran Medical Center in 2006, her internal medicine residency at Jacobi Medical Center/Albert Einstein College of Medicine in 2008 and her hematology and oncology fellowship at Tufts Medical Center/Tufts University School of Medicine in 2015.</p><p>Dr. Oh&rsquo;s research follows her clinical focus and has been shared through publication in peer-reviewed journals.</p><p>Dr. Oh is board certified in internal medicine, medical oncology and hematology. She is a member of the American Society of Clinical Oncology</p>

Is Open Scheduling

Off

Katharine A. McNeill

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/507c4f00-3934-11ed-9b41-f32856b0701a.jpg

First Name

Katharine

Last Name

McNeill

NPI

1598995730

Faculty ID

15494

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

1542

Is Open Scheduling

Off

Ioannis Mantzaris

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b67e5d80-3938-11ed-a06a-83625b154202.jpg

First Name

Ioannis

Last Name

Mantzaris

NPI

1871865519

Faculty ID

14586

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

57027

Is Open Scheduling

Off

Della F. Makower

https://assets.montefioreeinstein.org/profiles/images/physphoto/Makower_Della_MD_420x504.jpg

First Name

Della

Last Name

Makower

NPI

1578559910

Faculty ID

6729

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>My research is focused on breast cancer management, and on care delivery and support for breast cancer patients.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3965

Is Open Scheduling

Off